3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le jeudi 6 février 2020
Doi : 10.1016/j.jaad.2019.09.071
accepted : 14 September 2019
High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

Mondana H. Ghias, BS a, Andrew D. Johnston, MS a, Allison J. Kutner, MD a, Robert G. Micheletti, MD b, H. Dean Hosgood, PhD c, Steven R. Cohen, MD, MPH a,
a Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York 
b Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 
c Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York 

Reprint requests: Steven R. Cohen, MD, MPH, 3411 Wayne Ave, 2nd Floor, Ste D, Bronx, NY 10467.3411 Wayne Ave, 2nd Floor, Ste DBronxNY10467

The permanent disfigurement associated with hidradenitis suppurativa (HS) necessitates early aggressive disease intervention. Although limited data support the use of infliximab (IFX) in HS, the efficacy of high-dose, high-frequency IFX has yet to be defined.


To evaluate the efficacy of IFX 7.5 to 10 mg/kg, with a maintenance frequency every 4 weeks.


Prospective analysis of 42 patients initiating IFX 7.5 mg/kg every 4 weeks (IFX 7.5) and 16 patients receiving dose escalation to IFX 10 mg/kg every 4 weeks (IFX 10) between March 1, 2018, and February 28, 2019. The primary outcome measure (clinical response) was the proportion of patients with Physician Global Assessment of clear, minimal, or mild (score of 0-2) HS with at least a 2-grade improvement from baseline scores.


The proportion of patients achieving a clinical response after initiating IFX 7.5 was 20 of 42 (47.6%) at week 4 and 17 of 24 (70.8%) at week 12. For patients receiving dose escalation to IFX 10 because of incomplete initial response, 6 of 16 (37.5%) achieved clinical response at week 4 and 6 of 12 (50%) at week 12.


Initiation of IFX 7.5 every 4 weeks, with possible dose escalation to IFX 10, if needed, provides optimal mitigation of HS-related disease activity.

The full text of this article is available in PDF format.

Key words : acne inversa, anti-TNF, anti–TNF-α therapy, biologics, hidradenitis, hidradenitis suppurativa, high dose, high frequency, infliximab, TNF inhibitor

Abbreviations used : BMI, HS, IBD, IFX, IFX 5, IFX 7.5, IFX 10, MCID, NRS, PGA, SAE

 Funding sources: Mr Johnston was supported by the Albert Einstein College of Medicine Medical Scientist Training Program (NIH NIGMS T32 GM007288).
 Disclosure: Dr Cohen has served as principal investigator and on the advisory board for AbbVie, Inc, and on the advisory board for Verrica Pharmaceuticals. Ms Ghias, Mr Johnston, and Drs Kutner, Micheletti, and Hosgood have to conflicts of interest to declare.
 IRB approval status: Reviewed and approved by the Albert Einstein College of Medicine/Montefiore Medical Center IRB (2015-5906).
 Supplemental tables and figures available at 9mhhh2zjbb.2.

© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline